HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Baseline levels of PAR-4 secreted by normal cells are generally inadequate to cause massive
apoptosis in cancer cells and drugs that bolster the secretion of PAR-4 would constitute an
important therapeutic advance.The apoptosis sensitizing features of hydroxychloroquine
enhance the anti-tumor effects of a broad range of cancer therapeutics. The investigators
hypothesize that hydroxychloroquine will induce at least 2-fold increase in systemic (plasma)
PAR-4 levels compared to pre-treatment plasma levels in patients with resectable solid
tumors.